Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder

Abstract

Introduction: Adverse childhood experiences are associated with the development of substance use disorders. With opioid use disorder, a growing concern in the United States, we were interested in examining the relationship between adverse experiences and three landmarks of opioid use: age of opioid initiation, injection drug use, and lifetime overdose.

Methods: Between May and December 2015, we interviewed consecutive persons seeking inpatient opioid detoxification. Participants were asked about age of opioid initiation, last month injection drug use, and lifetime history of overdose, and completed the ten-item Adverse Childhood Experience (ACE) questionnaire.

Results: Participants (n=457) averaged 32.2 (±8.64) years of age, 71.3% were male, and 82.5% were non-Hispanic White. The mean score on the ACE scale was 3.64 (±2.75). Mean age at time of initiating opioid use was 21.7 (±7.1) years, 68.7% had injected drugs within the past month, and 39.0% had overdosed. After adjusting for age, gender, and ethnicity, the ACE score was inversely associated with age of initiating opioid use (b=-0.50, 95% CI -0.70; -0.29, p<.001), and positively associated with recent injection drug use (OR=1.11, 95% CI 1.02; 1.20, p=0.014) and the likelihood of experiencing an overdose (OR=1.10, 95% CI 1.02; 1.20, p=0.015) in a graded dose response manner.

Conclusion: Greater adverse childhood experiences are associated with three landmarks of opioid use risk. ACE screening may be useful in identifying high-risk subsets of opioid-using populations.

Trial registration: ClinicalTrials.gov NCT01751789.

Keywords: Adverse childhood experiences; Detoxification; Opiates.

Conflict of interest statement

Conflict of Interest

Dr. Bailey reports personal fees from BioDelivery Science International, Inc., grants, personal fees and other from Braeburn Pharmaceuticals, Inc., personal fees from Camurus AB, grants from Orexo, grants and other from Reckitt-Benckiser (Indivior), other from Titan Pharmaceuticals, Inc., outside the submitted work. (ICMJE form available upon request.)

Copyright © 2017 Elsevier B.V. All rights reserved.